Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced that the Japanese Patent Office has issued a decision to grant a key patent covering the composition, manufacture and use of Progenza stem cell technology.
Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced positive results from its Phase 1 safety trial of Progenza in patients with knee osteoarthritis, meeting the primary endpoint of safety and tolerability.
Rhinomed Ltd (ASX:RNO) (OTCMKTS:RHNMF) are pleased to provide the Company's latest Investor Update for May 2017.
Treatment for sleep apnoea usually involves either a mask or a mouthguard. A new Australian invention combines the best elements of both. Brisbane dentist Chris Hart spent years struggling to sleep. He snored constantly. He often woke up during the night because he had stopped breathing because of a n obstruction in his nose and throat.
Oventus Medical Ltd (ASX:OVN) is pleased to provide the Company's latest Investor Presentation.
Respiratory technology company Rhinomed (ASX:RNO) (OTCMKTS:RHNMF) is pleased to announce that it has been advised by Sigma Healthcare (ASX:SIG) that Mute sleep technology will form part of the 2017 core range for the Amcal and Guardian pharmacy brands.
Australian medical device company Oventus Medical Ltd. (ASX:OVN), has lodged an FDA 510k submission for its O2Vent W device - an oral appliance intended to reduce or alleviate snoring, mild to moderate obstructive sleep apnoea and severe sleep apnoea when the patient is intolerant to Continuous Positive Airway Pressure Devices.
